TP53 Mutations and Circulating Blasts ≥ 20% Are the Primary Determinants of Survival in Accelerated/Blast‐Phase Myeloproliferative Neoplasms Treated With Frontline Venetoclax Plus Hypomethylating Agent

Key Points

• To determine the factors influencing survival outcomes in patients with accelerated or blast-phase myeloproliferative neoplasms treated with venetoclax and hypomethylating agents.
• Analysis of survival outcomes among 82 patients at Mayo Clinic with MPN-BP/AP.
• Evaluation of TP53 mutations present in patients.
• Assessment of circulating blasts levels in patients.
• Patients with TP53 mutations had significantly lower survival rates.
• Elevated circulating blasts (≥20%) were associated with poorer survival outcomes.
• Combined analysis reveals that both TP53 mutations and circulating blasts are critical determinants of survival.